Exiqon Plans to Launch Two miRNA Diagnostics in 2014

The company also released its fourth-quarter financial results, posting sharply lower losses on reduced expenses, and said that a licensing dispute with Santaris has gone to arbitration.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories